The Latest Cardiac and Vascular News
ALAMEDA, Calif., Oct. 14, 2024 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. THUNDER is evaluating the safety and efficacy of the company’s…
Long-term outcomes data from ADVANCE-DK Registry with HeartFlow FFRCT and Plaque Analysis and ongoing clinical studies highlighting CCTA and FFRCT diagnostic pathway to be discussed in six presentations
DENVER–(BUSINESS WIRE)–Transverse Medical, Inc., developer of the POINT-GUARD™ Cerebral Embolic Protection medical device, is pleased to announce the appointment of Ian T. Meredith, MD to the Board of Directors. Professor Meredith brings over 35 years of experience and global leadership in cardiology coupled with successful clinical trials and device commercialization […]
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson1 (NYSE: JNJ) announced today it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. V-Wave will operate as part of Johnson & Johnson MedTech. The acquisition of V-Wave extends Johnson & Johnson […]
TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) — Conavi Medical Corp. (formerly, “Titan Medical Inc.”) (“the “Resulting Issuer” or the “Corporation”) (TSX: TMD; OTC: TMDIF) is pleased to announce the completion of the previously announced business combination between Conavi Medical Inc. (“Conavi”) and the Corporation in an all-stock transaction, which constituted a reverse takeover of the Corporation (the “Transaction”). The combined company (the Resulting Issuer) will focus on continuing to commercialize and develop Conavi’s Novasight Hybrid™ System designed to guide common minimally invasive coronary procedures.
Coverage policy improves access to artificial intelligence-enabled plaque analysis providing insights to help physicians guide treatment decisions for patients with coronary artery disease Coverage policy improves access to artificial intelligence-enabled plaque analysis providing insights to help physicians guide treatment decisions for patients with coronary artery disease
Tricuspid valve regurgitation can lead to enlarged heart, fatigue and heart failure; the condition affects 1.6 million Americans PITTSBURGH, Oct. 10, 2024 /PRNewswire-PRWeb/ — The cardiac team from Allegheny General Hospital (AGH), the academic flagship facility of Allegheny Health…
Enrollment completed ahead of schedule in the global IDE for Abbott’s Volt™ PFA System Global FOCALFLEX trial now underway for Abbott’s TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor™ HD Grid X Mapping Catheter, Sensor Enabled™, receives U.S. Food and Drug Administration…
Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif.,…
OKLAHOMA CITY, Oct. 9, 2024 /PRNewswire/ — OU Health, the flagship academic health system of the University of Oklahoma, has performed its first pediatric heart transplant in decades at Oklahoma Children’s Hospital OU Health, marking a significant milestone in pediatric cardiac care for…
